#Global Trends – Page 6 – HEALTHCARE INSIGHTS

Key Development On August 19, 2026, South Korean biopharmaceutical leader SK Biopharmaceuticals (KRX: 326030) formally concluded its first patent litigation... Read more

Tag: #Global Trends

Mass Tort Litigation Defense: Abbott Agrees to $670 Million Settlement to Resolve 2,000 Preterm Infant Formula Necrotizing Enterocolitis (NEC) Claims

Breakthrough in Personalized Oncology: Moderna and Merck’s Tailored mRNA Cancer Vaccine Intismeran Cuts Melanoma Recurrence and Metastasis in Landmark Phase 3 Trial – Moderna Shares Surge 160%

CNS Patent Defense & Market Exclusivity: SK Biopharmaceuticals Reaches Landmark Patent Settlement with MSN Laboratories to Protect U.S. Exclusivity for Anti-Epileptic Blockbuster Xcopri® (Cenobamate) Beyond 2032

Ultrarare Genetic Disease Milestone: FDA Approves Regeneron’s Pasatru® (Garetosmab) for Fibrodysplasia Ossificans Progressiva (FOP) – Delivering Up to 94% Reduction in New Heterotopic Bone Lesions

AI-Augmented Surgical Robotics: Johnson & Johnson MedTech Secures FDA 510(k) Clearance for Monarch Quest 3 Software Enhancing Robotic Bronchoscopy and Lung Nodule Targeting

Commercial Adaptation in the GLP-1 Era: Nestlé Leverages Artificial Intelligence and Nutritional Science to Develop Companion Product Portfolio for Weight-Loss Drug Users

Global Biosimilar Empire Expansion: Sandoz Signs $322 Million Licensing Deal with Shanghai Henlius for Biosimilar Copies of Repatha®, Benlysta®, and Erbitux®

Precision Oncology Clinical Readouts: AstraZeneca Announces Phase 3 Wins for Enhertu® and Orpathys®-Tagrisso® in NSCLC Amid Volrustomig Bispecific Setback

Intellectual Property Enforcement: Eli Lilly Files Federal Lawsuits Against Six Entities Over Illegal Commercialization of Experimental Obesity Drug Retatrutide

Facebook

Map

Online Members